ABT-348 as Monotherapy and in Combination With Azacitidine to Treat Advanced Hematologic Malignancies
Status:
Completed
Trial end date:
2013-06-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine the safety, pharmacokinetics and maximum tolerated
dose of ABT-348 as monotherapy and when given in combination with azacitidine.